Vaccines and AMR: An analysis of the funding landscape for human bacterial vaccines in low-and middle-income countries
Comprehensive and transparent reporting is needed to accurately assess funding to LMICs. Nevertheless, the current analysis shows that PDPs and intermediary funders are pivotal in ensuring investments reach LMIC product developers. Data gaps remain for critical bacterial pathogens on WHO's AMR priority pathogen list.
Authors
- Jérôme H. Kim (ORCID: https://orcid.org/0000-0003-0461-6438)
- Laura Plant (ORCID: https://orcid.org/0000-0001-7236-8718)
- Christiane Gerke
- Lesley A. Ogilvie (ORCID: https://orcid.org/0000-0001-9794-2915)
- Ralf Sudbrak (ORCID: https://orcid.org/0000-0001-8825-0503)
- Usha Lamichhane
- T. Anh Wartel (ORCID: https://orcid.org/0009-0006-2693-9560)
- Anton Doubell (ORCID: https://orcid.org/0009-0005-7699-8684)
- Catherine Fleck-Vidal
Institutions
- International Vaccine Institute (KR)
- The George Institute for Global Health (AU)
Publication Details
- Journal
- Vaccine
- Published
- 2025-01-29
- DOI
- https://doi.org/10.1016/j.vaccine.2025.126771
- Citations
- 1
- Primary Topic
- Antibiotic Use and Resistance
- Type
- article
- Field-Weighted Citation Impact
- 1.26
Funders
- Bundesministerium für Bildung und Forschung
- Utrikesdepartementet